枯草杆菌肠球菌二联活菌胶囊对非酒精性脂肪性肝炎患者血清内毒素水平的影响

doi:10.3969/j.issn.1672-5069.2012.02.007

实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (2): 101-103.doi: 10.3969/j.issn.1672-5069.2012.02.007

枯草杆菌肠球菌二联活菌胶囊对非酒精性脂肪性肝炎患者血清内毒素水平的影响

杨林辉, 郭昭友, 曹明, 向姝, 刘国栋, 谭朝霞

400061 重庆市武警总队医院消化内科（杨林辉,郭昭友,曹明,向姝）;
第三军医大学附属西南医院感染病研究所（刘国栋,谭朝霞）

收稿日期:2012-01-09 出版日期:2012-04-10 发布日期:2017-03-07
作者简介:杨林辉男,40岁,医学硕士,主治医师。主要从事非酒精性脂肪肝的基础及临床研究。E-mail：dzswjyy@163.com

Effect of capsule containing bacillus subtilis and enterococcus on levels of serum endotoxin in patients with NASH

Yang Linhui, Guo Zhaoyou, Cao Ming, et al.

Department of Gastroenterology,Chongqing Municipal Corps Hospital,Chongqing 400061,China

Received:2012-01-09 Online:2012-04-10 Published:2017-03-07

摘要/Abstract

摘要： 目的探讨枯草杆菌肠球菌二联活菌胶囊对非酒精性脂肪性肝炎（NASH）患者肠道通透性及血清内毒素水平的影响。方法选择健康正常成人30例作为正常对照组和非酒精性脂肪性肝炎患者60例,给予后者枯草杆菌肠球菌二联活菌胶囊治疗4周。检测所有被研究者血清内毒素、二胺氧化酶（DAO）、D-乳酸及ALT水平。结果与对照组比较,治疗前患者内毒素、DAO、D-乳酸水平显著增高【分别为143.60±21.41EU/l对109.78±17.81EU/l（t=7.71,P<0.01）;2.6±0.47U/ml对2.3±0.48U/ml（t=2.24,P<0.05）;6.1±1.05mg/l对5.3±0.97mg/l（t=4.89,P<0.01）】;NASH患者治疗后与治疗前比较,内毒素、DAO、D-乳酸及ALT水平显著降低。结论非酒精性脂肪性肝炎患者肠道通透性及血清内毒素水平增高,微生态制剂枯草杆菌肠球菌二联活菌胶囊可降低肠道通透性、血清内毒素及ALT水平。

关键词: 非酒精性脂肪性肝炎, 肠道通透性, 枯草杆菌肠球菌二联活菌, 内毒素

Abstract: Objective To investigate the effect of microecological products capsule containing bacillus subtilis and enterococcus（Medilac-S） on the alteration of intestinal permeability and levels of serum endotoxin in patients with nonalcoholic steatohepatitis（NASH）. Methods Thirty healthy adults and sixty patients with NASH were included in this study.Their serum endotoxin,diamine oxidase, D-lactate and ALT levels were measured respectively.The patients with NASH were treated with Medilac-S for 4 weeks. Results Compared with control,the serum endotoxin,diamine oxidase,and D-lactate levels in patients with NASH increased [143.60±21.41EU/l vs 109.78±17.81EU/l（t=7.71,P<0.01）;2.6±0.47U/ml vs 2.3±0.48U/ml（t=2.24,P<0.05）; and 6.1±1.05mg/l vs 5.3±0.97mg/l（t=4.89,P<0.01）,respectively];after four week treatment with Medilac-S,the serum endotoxin,diamine oxidase,D-lactate and ALT levels decreased remarkably. Conclusions Medilac-S could effectively decrease intestinal permeability and levels of serum endotoxin and ALT in patients with NASH.

Key words: NASH, Intestinal permeability, Microecological products, Bacillus subtilis, Enterococcus, Endotoxin

杨林辉, 郭昭友, 曹明, 向姝, 刘国栋, 谭朝霞. 枯草杆菌肠球菌二联活菌胶囊对非酒精性脂肪性肝炎患者血清内毒素水平的影响[J]. 实用肝脏病杂志, 2012, 15(2): 101-103.

Yang Linhui, Guo Zhaoyou, Cao Ming, et al.. Effect of capsule containing bacillus subtilis and enterococcus on levels of serum endotoxin in patients with NASH[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(2): 101-103.

参考文献

[1] Peter LM. Non-alcoholic steatohepatitis. Eur J Gastroenterol Hepatol,2004,16（11）:1079-1085.
[2] Bugianesi E,Leone N,Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis:from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology,2002,123（1）:134-140.
[3] 赵龙凤,贾军梅,韩德五. 肠源性内毒素血症在非酒精性脂肪性肝炎发病中的作用. 中华肝脏病杂志,2004,12（10）:632-632.
[4] Wigg AJ,Roberts-Thomson IC,Dymock RB,et al. The role of small intestinal bacterial overgrowth,intestinal permeability,endotoxaemia,and tumor necrosis factor[alpha] in the pathogenesis of non-alcoholic steatohepatitis. Gut,2001,48（20）:206-211.
[5] Ester V,Elisabetta B. The gut-liver axis in nonalcoholic fatty liver disease:Another pathway to insulin resistance. Hepatology, 2009,49（6）:1791-1793.
[6] 中华医学会肝病学分会脂肪肝与酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 中华肝脏病杂志,2010,18（3）：163-166.
[7] 何桂珍.肠道通透性测定及临床意义.中华胃肠外科杂志, 2011,14（3）：226-228.
[8] 夏阳,秦环龙. 肠道屏障功能的临床评估方法. 中国实用外科杂志,2008,28（11）:1006-1008
[9] Han DW. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol,2002,8（6）:961-965.
[10] Markel TA,Crisostomo PR,Wairiuko GM,et a1. Cytokinesin necrotizing enterocolitis.Shock,2006,25（4）:329-337.
[11] Yee SB,Harkema JR,Ganey PE,et a1. The coagulation system contributes to synergistic liver injury from exposure to monocrotaline and bacterial lipopolysaccharide. Toxicol Sci,2003:74（2）:457-469.
[12] Hirose M,Nishikawa M,Qian W,et a1. Mannose-conjugated alendronate selectively depletes Kupffer cells and inhibits endotoxemic shock in the mice. Hepatol Res,2006,36（1）:3-10.
[13] Higuchi Y,Kawakami S,Yamashita F,et a1. The potential role of fucosylated cationic liposome/NFkaPPaB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials,2007,28（26）:532-539.
[14] Hart AL,Stagg AJ,Frame M,et al.The role of the gut flora in health and disease and its modification as therapy. Aliment Pharmacol Ther,2002,16（8）:1383-1393.
[15] 潘莉,韩真.脂肪细胞因子在非酒精性脂肪肝发病机制中的作用. 实用肝脏病杂志,2010,13（2）：151-153.
[16] 徐正婕,范建高,王国良,等. 小剂量内毒素致非酒精性脂肪性肝炎大鼠急性肝功能衰竭. 中华肝脏病杂志,2004,12（4）：244-245.
[17] Kim YG,Moon JT,Lae KM,et al. The efects of probioties on symptoms of irritable bowel syndrome. Korean J Gastroenteml,2006,47（6）：413-419.
[18] 牟方宏,胡伏莲. 又一新的微生态制剂—美常安.临床医学杂志,2004,2（5）：60.
[19] 袁杰利,傅晓丽,文妹,等. 屎肠球菌活菌制剂的研究. 中国微生态学杂志,2003,15（1）：20-21.

枯草杆菌肠球菌二联活菌胶囊对非酒精性脂肪性肝炎患者血清内毒素水平的影响

Effect of capsule containing bacillus subtilis and enterococcus on levels of serum endotoxin in patients with NASH

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[2]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[3]	李梦婷, 李兵航, 周达, 丁永年, 陈源文, 范建高. 非酒精性脂肪性肝病小鼠肝组织脯氨酰内肽酶蛋白及其活性变化^*[J]. 实用肝脏病杂志, 2018, 21(4): 549-552.
[4]	刘晓琳, 信丰智, 杨蕊旭, 赵泽华, 周达, 潘勤, 范建高. 茵栀黄口服液对非酒精性脂肪性肝炎大鼠肝脂肪变的保护作用研究*[J]. 实用肝脏病杂志, 2018, 21(3): 380-383.
[5]	池肇春. 非酒精性脂肪性肝炎肝硬化发病机制研究进展与展望[J]. 实用肝脏病杂志, 2018, 21(2): 166-169.
[6]	李鑫, 王洪岩, 迟程, 徐有青. 小檗碱对内毒素刺激致Caco-2细胞间高通透性的保护作用^*[J]. 实用肝脏病杂志, 2018, 21(1): 34-37.
[7]	陈光耀, 韩际奥, 周东晓, 高晓, 马英杰. 肝硬化患者小肠细菌过度生长及其外周血单个核细胞TLR4表达的变化[J]. 实用肝脏病杂志, 2017, 20(6): 728-731.
[8]	刘性涛. 慢加急性乙型肝炎肝衰竭患者血清内毒素和SIRS发生对多器官功能衰竭的影响[J]. 实用肝脏病杂志, 2017, 20(6): 758-759.
[9]	陈娟, 孔维宗, 梁凯, 王迎春. 白藜芦醇对非酒精性脂肪性肝炎大鼠肝组织SIRT3表达的影响^*[J]. 实用肝脏病杂志, 2017, 20(4): 402-407.
[10]	刘晓妮, 王颖, 李桃桃, 马小敏. 非酒精性脂肪性肝病合并2型糖尿病患者肝组织病理学变化研究[J]. 实用肝脏病杂志, 2017, 20(4): 420-423.
[11]	余红艳, 邸阜生. 关注2型糖尿病合并非酒精性脂肪性肝病的肝脏结局[J]. 实用肝脏病杂志, 2017, 20(3): 267-270.
[12]	贾艳红, 李相迁, 赵彩彦. 炎症小体与非酒精性脂肪性肝炎[J]. 实用肝脏病杂志, 2017, 20(3): 377-380.
[13]	何杰雄, 王鹏, 李静. 复方牛胎肝提取物治疗非酒精性脂肪性肝炎临床观察[J]. 实用肝脏病杂志, 2016, 19(5): 557-560.
[14]	尤娜综述, 朱进, 汪茂荣审校. 枯否氏细胞在肝损伤中的作用研究进展[J]. 实用肝脏病杂志, 2016, 19(5): 633-636.
[15]	信丰智, 范建高. 欧洲非酒精性脂肪性肝病诊疗指南简介[J]. 实用肝脏病杂志, 2016, 19(4): 511-511.